DDInter154 DDInter1007
Azelastine is a phthalazine compound having an oxo substituent at the 1-position, a 1-methylazepan-4-yl group at the 2-position and a 4-chlorobenzyl substituent at the 4-position. It has a role as a H1-receptor antagonist, an anti-allergic agent, an anti-asthmatic drug, a bronchodilator agent, a platelet aggregation inhibitor and an EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor. It is a member of phthalazines, a tertiary amino compound and a member of monochlorobenzenes.
Ketamine is an NMDA receptor antagonist with a potent anesthetic effect. It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories. It started being used for veterinary purposes in Belgium and in 1964 was proven that compared to PCP, it produced minor hallucinogenic effects and shorter psychotomimetic effects. It was FDA approved in 1970, and from there, it has been used as an anesthetic for children or patients undergoing minor surgeries but mainly for veterinary purposes.
Azelastine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ketamine
Azelastine {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Ketamine
Azelastine {u} (Compound) resembles {v} (Compound) Clemastine
Clemastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ketamine
Azelastine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Dronabinol
Dronabinol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ketamine
Azelastine {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Metoclopramide
Metoclopramide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ketamine
Azelastine {u} (Compound) causes {v} (Side Effect) Pain
Pain {u} (Side Effect) is caused by {v} (Compound) Sibutramine
Sibutramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ketamine
Azelastine {u} (Compound) downregulates {v} (Gene) STUB1
STUB1 {u} (Gene) interacts with {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ketamine
Azelastine {u} (Compound) resembles {v} (Compound) Clemastine
Clemastine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ketamine
Azelastine {u} (Compound) downregulates {v} (Gene) STUB1
STUB1 {u} (Gene) is downregulated by {v} (Compound) Salmeterol
Salmeterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ketamine
Azelastine {u} (Compound) resembles {v} (Compound) Clemastine
Clemastine {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Ketamine
Azelastine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ketamine (Compound)
Azelastine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Ketamine (Compound)
Azelastine (Compound) resembles Clemastine (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Ketamine
Azelastine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dronabinol (Compound) and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Ketamine
Azelastine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Metoclopramide (Compound) and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Ketamine
Azelastine (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Sibutramine (Compound) and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Ketamine
Azelastine (Compound) downregulates STUB1 (Gene) and STUB1 (Gene) interacts with CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ketamine (Compound)
Azelastine (Compound) resembles Clemastine (Compound) and Clemastine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ketamine (Compound)
Azelastine (Compound) downregulates STUB1 (Gene) and STUB1 (Gene) is downregulated by Salmeterol (Compound) and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Ketamine
Azelastine (Compound) resembles Clemastine (Compound) and Clemastine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Ketamine (Compound)